FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3175261378> ?p ?o ?g. }

• W3175261378 endingPage "508.e10" @default.
• W3175261378 startingPage "508.e1" @default.
• W3175261378 abstract "Background In women with BRCA mutations, risk-reducing bilateral salpingo-oophorectomy has been shown to decrease gynecologic cancer–specific and overall mortality. The National Comprehensive Cancer Network recommends that patients with BRCA mutations undergo risk-reducing bilateral salpingo-oophorectomy between the ages of 35 and 40 years for BRCA1 mutation carriers and between the ages of 40 and 45 years for BRCA2 mutation carriers or after childbearing is complete. Currently, uptake and timing of risk-reducing bilateral salpingo-oophorectomy and reasons for delays in risk-reducing bilateral salpingo-oophorectomy are not well understood. Objective We sought to evaluate uptake and timing of risk-reducing bilateral salpingo-oophorectomy among women with BRCA1 and BRCA2 mutations concerning the National Comprehensive Cancer Network guidelines and reasons for delays in risk-reducing bilateral salpingo-oophorectomy. Study Design In this retrospective chart review, we identified women with BRCA1 and BRCA2 mutations who discussed risk-reducing bilateral salpingo-oophorectomy with a provider between 2012 and 2021. Uptake of risk-reducing bilateral salpingo-oophorectomy was documented, and patients were classified as having timely or delay in risk-reducing bilateral salpingo-oophorectomy based on the National Comprehensive Cancer Network guidelines. For those with delay in risk-reducing bilateral salpingo-oophorectomy, reasons cited for delay were collected. Comparative statistical analyses were performed to evaluate characteristics of those with timely vs delayed risk-reducing bilateral salpingo-oophorectomy. A multivariable logistic regression model was used to evaluate the associations among factors related to timing of risk-reducing bilateral salpingo-oophorectomy. Results We identified 638 BRCA1 and BRCA2 mutation carriers seen between 2012 and 2021. Of these patients, 306 (48.0%) had undergone risk-reducing bilateral salpingo-oophorectomy and 332 (52.0%) had not. When evaluating the timing of risk-reducing bilateral salpingo-oophorectomy, 136 (21.3%) underwent timely risk-reducing bilateral salpingo-oophorectomy, 239 (37.5%) had delays in risk-reducing bilateral salpingo-oophorectomy, and 263 (41.2%) had not undergone risk-reducing bilateral salpingo-oophorectomy but were younger than the National Comprehensive Cancer Network age guidelines; therefore, they were neither timely nor delayed. Patients with delay in risk-reducing bilateral salpingo-oophorectomy were significantly older at the time of genetic testing than those with timely risk-reducing bilateral salpingo-oophorectomy (mean, 49.8 vs 36.3 years; P<.001). Of the 306 patients who underwent risk-reducing bilateral salpingo-oophorectomy, those with delayed risk-reducing bilateral salpingo-oophorectomy had a significantly shorter interval between BRCA identification and risk-reducing bilateral salpingo-oophorectomy than those with timely risk-reducing bilateral salpingo-oophorectomy (median, 8.7 vs 17.6 months; P<.001). Patients with delay in risk-reducing bilateral salpingo-oophorectomy were more likely to have a personal history of cancer than those with timely risk-reducing bilateral salpingo-oophorectomy (49.8% vs 37.5%; P=.028). Of the 239 women with delay in risk-reducing bilateral salpingo-oophorectomy, 188 (78.7%) had delayed BRCA mutation identification, 29 (12.1%) had menopausal concerns, 17 (7.1%) had ongoing cancer treatment, 12 (5.0%) had coordination with breast surgery, 20 (8.4%) had miscellaneous reasons, and 19 (7.9%) had no reason documented. In the multivariate model, older age at BRCA diagnosis (odds ratio, 0.73; 95% confidence interval, 0.68–0.78; P<.001) was significantly associated with delayed risk-reducing bilateral salpingo-oophorectomy timing; those with BRCA2 mutation type were 7.54 times as likely to have timely risk-reducing bilateral salpingo-oophorectomy than BRCA1 mutation carriers (odds ratio, 7.54; 95% confidence, 3.70–16.42; P<.001). Conclusion Nearly 38% of BRCA1 and BRCA2 mutation carriers undergo or have yet to undergo risk-reducing bilateral salpingo-oophorectomy over the recommended National Comprehensive Cancer Network age. The most common reason for the delay in risk-reducing bilateral salpingo-oophorectomy was delayed identification of BRCA mutation, noted in 79% of patients with delayed risk-reducing bilateral salpingo-oophorectomy. Timely genetic testing for eligible patients can increase appropriately timed risk-reducing bilateral salpingo-oophorectomy for the prevention of ovarian cancer and reduction of mortality in BRCA mutation carriers. In women with BRCA mutations, risk-reducing bilateral salpingo-oophorectomy has been shown to decrease gynecologic cancer–specific and overall mortality. The National Comprehensive Cancer Network recommends that patients with BRCA mutations undergo risk-reducing bilateral salpingo-oophorectomy between the ages of 35 and 40 years for BRCA1 mutation carriers and between the ages of 40 and 45 years for BRCA2 mutation carriers or after childbearing is complete. Currently, uptake and timing of risk-reducing bilateral salpingo-oophorectomy and reasons for delays in risk-reducing bilateral salpingo-oophorectomy are not well understood. We sought to evaluate uptake and timing of risk-reducing bilateral salpingo-oophorectomy among women with BRCA1 and BRCA2 mutations concerning the National Comprehensive Cancer Network guidelines and reasons for delays in risk-reducing bilateral salpingo-oophorectomy. In this retrospective chart review, we identified women with BRCA1 and BRCA2 mutations who discussed risk-reducing bilateral salpingo-oophorectomy with a provider between 2012 and 2021. Uptake of risk-reducing bilateral salpingo-oophorectomy was documented, and patients were classified as having timely or delay in risk-reducing bilateral salpingo-oophorectomy based on the National Comprehensive Cancer Network guidelines. For those with delay in risk-reducing bilateral salpingo-oophorectomy, reasons cited for delay were collected. Comparative statistical analyses were performed to evaluate characteristics of those with timely vs delayed risk-reducing bilateral salpingo-oophorectomy. A multivariable logistic regression model was used to evaluate the associations among factors related to timing of risk-reducing bilateral salpingo-oophorectomy. We identified 638 BRCA1 and BRCA2 mutation carriers seen between 2012 and 2021. Of these patients, 306 (48.0%) had undergone risk-reducing bilateral salpingo-oophorectomy and 332 (52.0%) had not. When evaluating the timing of risk-reducing bilateral salpingo-oophorectomy, 136 (21.3%) underwent timely risk-reducing bilateral salpingo-oophorectomy, 239 (37.5%) had delays in risk-reducing bilateral salpingo-oophorectomy, and 263 (41.2%) had not undergone risk-reducing bilateral salpingo-oophorectomy but were younger than the National Comprehensive Cancer Network age guidelines; therefore, they were neither timely nor delayed. Patients with delay in risk-reducing bilateral salpingo-oophorectomy were significantly older at the time of genetic testing than those with timely risk-reducing bilateral salpingo-oophorectomy (mean, 49.8 vs 36.3 years; P<.001). Of the 306 patients who underwent risk-reducing bilateral salpingo-oophorectomy, those with delayed risk-reducing bilateral salpingo-oophorectomy had a significantly shorter interval between BRCA identification and risk-reducing bilateral salpingo-oophorectomy than those with timely risk-reducing bilateral salpingo-oophorectomy (median, 8.7 vs 17.6 months; P<.001). Patients with delay in risk-reducing bilateral salpingo-oophorectomy were more likely to have a personal history of cancer than those with timely risk-reducing bilateral salpingo-oophorectomy (49.8% vs 37.5%; P=.028). Of the 239 women with delay in risk-reducing bilateral salpingo-oophorectomy, 188 (78.7%) had delayed BRCA mutation identification, 29 (12.1%) had menopausal concerns, 17 (7.1%) had ongoing cancer treatment, 12 (5.0%) had coordination with breast surgery, 20 (8.4%) had miscellaneous reasons, and 19 (7.9%) had no reason documented. In the multivariate model, older age at BRCA diagnosis (odds ratio, 0.73; 95% confidence interval, 0.68–0.78; P<.001) was significantly associated with delayed risk-reducing bilateral salpingo-oophorectomy timing; those with BRCA2 mutation type were 7.54 times as likely to have timely risk-reducing bilateral salpingo-oophorectomy than BRCA1 mutation carriers (odds ratio, 7.54; 95% confidence, 3.70–16.42; P<.001). Nearly 38% of BRCA1 and BRCA2 mutation carriers undergo or have yet to undergo risk-reducing bilateral salpingo-oophorectomy over the recommended National Comprehensive Cancer Network age. The most common reason for the delay in risk-reducing bilateral salpingo-oophorectomy was delayed identification of BRCA mutation, noted in 79% of patients with delayed risk-reducing bilateral salpingo-oophorectomy. Timely genetic testing for eligible patients can increase appropriately timed risk-reducing bilateral salpingo-oophorectomy for the prevention of ovarian cancer and reduction of mortality in BRCA mutation carriers." @default.
• W3175261378 created "2021-07-05" @default.
• W3175261378 creator A5002504968 @default.
• W3175261378 creator A5007605375 @default.
• W3175261378 creator A5009393372 @default.
• W3175261378 creator A5023495325 @default.
• W3175261378 creator A5029564912 @default.
• W3175261378 creator A5031214385 @default.
• W3175261378 creator A5037954928 @default.
• W3175261378 creator A5049020791 @default.
• W3175261378 date "2021-11-01" @default.
• W3175261378 modified "2023-09-25" @default.
• W3175261378 title "Uptake and timing of risk-reducing salpingo-oophorectomy among patients with BRCA1 and BRCA2 mutations" @default.
• W3175261378 cites W1484356204 @default.
• W3175261378 cites W1484359909 @default.
• W3175261378 cites W1571636432 @default.
• W3175261378 cites W1577886831 @default.
• W3175261378 cites W1971245074 @default.
• W3175261378 cites W1998197289 @default.
• W3175261378 cites W1998928377 @default.
• W3175261378 cites W2001532410 @default.
• W3175261378 cites W2011515749 @default.
• W3175261378 cites W2025402387 @default.
• W3175261378 cites W2036884664 @default.
• W3175261378 cites W2045733577 @default.
• W3175261378 cites W2046536401 @default.
• W3175261378 cites W2049077879 @default.
• W3175261378 cites W2065420818 @default.
• W3175261378 cites W2067560254 @default.
• W3175261378 cites W2079144646 @default.
• W3175261378 cites W2080492206 @default.
• W3175261378 cites W2087979878 @default.
• W3175261378 cites W2099000973 @default.
• W3175261378 cites W2115073715 @default.
• W3175261378 cites W2117576401 @default.
• W3175261378 cites W2135525536 @default.
• W3175261378 cites W2149994587 @default.
• W3175261378 cites W2155586874 @default.
• W3175261378 cites W2477586529 @default.
• W3175261378 cites W2572458419 @default.
• W3175261378 cites W2589697688 @default.
• W3175261378 cites W2753685787 @default.
• W3175261378 cites W2774277363 @default.
• W3175261378 cites W2938370698 @default.
• W3175261378 cites W2999462612 @default.
• W3175261378 cites W3005915410 @default.
• W3175261378 cites W3015141169 @default.
• W3175261378 cites W3029077617 @default.
• W3175261378 cites W3118983547 @default.
• W3175261378 doi "https://doi.org/10.1016/j.ajog.2021.06.070" @default.
• W3175261378 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34171390" @default.
• W3175261378 hasPublicationYear "2021" @default.
• W3175261378 type Work @default.
• W3175261378 sameAs 3175261378 @default.
• W3175261378 citedByCount "13" @default.
• W3175261378 countsByYear W31752613782022 @default.
• W3175261378 countsByYear W31752613782023 @default.
• W3175261378 crossrefType "journal-article" @default.
• W3175261378 hasAuthorship W3175261378A5002504968 @default.
• W3175261378 hasAuthorship W3175261378A5007605375 @default.
• W3175261378 hasAuthorship W3175261378A5009393372 @default.
• W3175261378 hasAuthorship W3175261378A5023495325 @default.
• W3175261378 hasAuthorship W3175261378A5029564912 @default.
• W3175261378 hasAuthorship W3175261378A5031214385 @default.
• W3175261378 hasAuthorship W3175261378A5037954928 @default.
• W3175261378 hasAuthorship W3175261378A5049020791 @default.
• W3175261378 hasConcept C126322002 @default.
• W3175261378 hasConcept C131872663 @default.
• W3175261378 hasConcept C141071460 @default.
• W3175261378 hasConcept C143998085 @default.
• W3175261378 hasConcept C2777696064 @default.
• W3175261378 hasConcept C2779494336 @default.
• W3175261378 hasConcept C29456083 @default.
• W3175261378 hasConcept C71924100 @default.
• W3175261378 hasConceptScore W3175261378C126322002 @default.
• W3175261378 hasConceptScore W3175261378C131872663 @default.
• W3175261378 hasConceptScore W3175261378C141071460 @default.
• W3175261378 hasConceptScore W3175261378C143998085 @default.
• W3175261378 hasConceptScore W3175261378C2777696064 @default.
• W3175261378 hasConceptScore W3175261378C2779494336 @default.
• W3175261378 hasConceptScore W3175261378C29456083 @default.
• W3175261378 hasConceptScore W3175261378C71924100 @default.
• W3175261378 hasIssue "5" @default.
• W3175261378 hasLocation W31752613781 @default.
• W3175261378 hasOpenAccess W3175261378 @default.
• W3175261378 hasPrimaryLocation W31752613781 @default.
• W3175261378 hasRelatedWork W195837920 @default.
• W3175261378 hasRelatedWork W1998826110 @default.
• W3175261378 hasRelatedWork W1999344589 @default.
• W3175261378 hasRelatedWork W2039417803 @default.
• W3175261378 hasRelatedWork W2079452639 @default.
• W3175261378 hasRelatedWork W2085279352 @default.
• W3175261378 hasRelatedWork W2391778245 @default.
• W3175261378 hasRelatedWork W2783428915 @default.
• W3175261378 hasRelatedWork W2789448498 @default.
• W3175261378 hasRelatedWork W4250651714 @default.
• W3175261378 hasVolume "225" @default.
• W3175261378 isParatext "false" @default.

• next